Literature DB >> 18695002

Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Connie Duckers1, Paolo Simioni, Luca Spiezia, Claudia Radu, Sabrina Gavasso, Jan Rosing, Elisabetta Castoldi.   

Abstract

Severe factor V (FV) deficiency is associated with mild to severe bleeding diathesis, but many patients with FV levels lower than 1% bleed less than anticipated. We used calibrated automated thrombography to screen patients with severe FV deficiency for protective procoagulant defects. Thrombin generation in FV-deficient plasma was only measurable at high tissue factor concentrations. Upon reconstitution of FV-deficient plasma with purified FV, thrombin generation increased steeply with FV concentration, reaching a plateau at approximately 10% FV. FV-deficient plasma reconstituted with 100% FV generated severalfold more thrombin than normal plasma, especially at low tissue factor concentrations (1.36 pM) or in the presence of activated protein C, suggesting reduced tissue factor pathway inhibitor (TFPI) levels in FV-deficient plasma. Plasma TFPI antigen and activity levels were indeed lower (P < .001) in FV-deficient patients (n = 11; 4.0 +/- 1.0 ng/mL free TFPI) than in controls (n = 20; 11.5 +/- 4.8 ng/mL), while persons with partial FV deficiency had inter-mediate levels (n = 16; 7.9 +/- 2.5 ng/mL). FV immunodepletion experiments in normal plasma and surface plasmon resonance analysis provided evidence for the existence of a FV/TFPI complex, possibly affecting TFPI stability/clearance in vivo. Low TFPI levels decreased the FV requirement for minimal thrombin generation in FV-deficient plasma to less than 1% and might therefore protect FV-deficient patients from severe bleeding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695002      PMCID: PMC2572790          DOI: 10.1182/blood-2008-06-162453

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V.

Authors:  J Cui; K S O'Shea; A Purkayastha; T L Saunders; D Ginsburg
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

2.  Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene.

Authors:  J F Guasch; S Cannegieter; P H Reitsma; E T van't Veer-Korthof; R M Bertina
Journal:  Br J Haematol       Date:  1998-04       Impact factor: 6.998

3.  A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI).

Authors:  A E A Dahm; T O Andersen; F Rosendaal; P M Sandset
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

Review 4.  The anticoagulant protein C pathway.

Authors:  Björn Dahlbäck; Bruno O Villoutreix
Journal:  FEBS Lett       Date:  2005-03-13       Impact factor: 4.124

5.  Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.

Authors:  R A Ariëns; G Alberio; M Moia; P M Mannucci
Journal:  Thromb Haemost       Date:  1999-02       Impact factor: 5.249

6.  Symptoms of inherited factor V deficiency in 35 Iranian patients.

Authors:  M Lak; R Sharifian; F Peyvandi; P M Mannucci
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

7.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

8.  The increase with age of the components of the tissue factor coagulation pathway is gender-dependent.

Authors:  R A Ariëns; R Coppola; I Potenza; P M Mannucci
Journal:  Blood Coagul Fibrinolysis       Date:  1995-07       Impact factor: 1.276

9.  Heterogeneity of plasma tissue factor pathway inhibitor.

Authors:  G J Broze; G W Lange; K L Duffin; L MacPhail
Journal:  Blood Coagul Fibrinolysis       Date:  1994-08       Impact factor: 1.276

10.  Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.

Authors:  G A Nicolaes; G Tans; M C Thomassen; H C Hemker; I Pabinger; K Varadi; H P Schwarz; J Rosing
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

View more
  41 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

Review 2.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

3.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.

Authors:  Kenichi Ogiwara; Keiji Nogami; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

4.  Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.

Authors:  George J Broze; Thomas J Girard
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

5.  Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Authors:  Matthew W Bunce; Mettine H A Bos; Sriram Krishnaswamy; Rodney M Camire
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

6.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

7.  Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Authors:  Kanagasabai Vadivel; Sathya-Moorthy Ponnuraj; Yogesh Kumar; Anne K Zaiss; Matthew W Bunce; Rodney M Camire; Ling Wu; Denis Evseenko; Harvey R Herschman; Madhu S Bajaj; S Paul Bajaj
Journal:  J Biol Chem       Date:  2014-09-28       Impact factor: 5.157

8.  Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency.

Authors:  Beth A Bouchard; John Chapin; Kathleen E Brummel-Ziedins; Peter Durda; Nigel S Key; Paula B Tracy
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

9.  Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study.

Authors:  Joline L Saes; Marieke J A Verhagen; Karina Meijer; Marjon H Cnossen; Roger E G Schutgens; Marjolein Peters; Laurens Nieuwenhuizen; Felix J M van der Meer; Ilmar C Kruis; Waander L van Heerde; Saskia E M Schols
Journal:  Blood Adv       Date:  2020-10-27

Review 10.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.